What is ZYME's current stock price?

ZYME (Zymeworks Inc.) is currently trading at $25.61 with a market cap of $1.88B.

What sector is Zymeworks Inc. in?

Zymeworks Inc. (ZYME) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is ZYME a good stock to buy?

Analysts have a Buy consensus on ZYME with a price target of $38.25. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

ZYME Zymeworks Inc.

Healthcare

$25.61+1.99%ClosedMarket Cap: $1.88B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.01

P/S

23.19

EV/EBITDA

2025.69

DCF Value

$-18.31

FCF Yield

-2428.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

94.4%

Operating Margin

-140.4%

Net Margin

-126.3%

ROE

-0.2%

ROA

-0.0%

ROIC

-0.0%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$2.4M	$-44.2M	$—
Q4 null	$2.5M	$-41.2M	$—
FY null	$106.0M	$-81.1M	$—
Q3 null	$27.6M	$-19.6M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$38.25

Target (Median)

$36.50

Target Range

$32.00 - $48.00

2 Strong Buy12 Buy0 Hold0 Sell0 Strong Sell

Wells FargoOverweight

2026-05-08

Evercore ISI GroupOutperform

2026-03-09

HC Wainwright & Co.Buy

2026-03-06

Leerink PartnersOutperform

2026-03-03

StifelBuy

2026-03-03

Trading Activity

Insider Trades

View All

Schneider Paul Rofficer: EVP, General Counsel

SellFri May 15

Schneider Paul Rofficer: EVP, General Counsel

SellFri May 15

Schneider Paul Rofficer: EVP, General Counsel

SellFri May 15

Schayowitz Adamofficer: See Remarks

SellFri Apr 10

Schayowitz Adamofficer: See Remarks

SellFri Apr 10

Latest News

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026GlobeNewsWire · Tue Apr 21

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.19

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

Peers

UPB